Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 6, 2009, Pages 1129-1137

  Kano, Yasuhiko ^a   Tanaka, Masaru ^a   Akutsu, Miyuki ^a   Mori, Kiyoshi ^a   Yazawa, Yasuo ^a   Mano, Hiroyuki ^b   Furukawa, Yusuke ^b  

^a TOCHIGI CANCER CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Docetaxel; Isobologram; Lung cancer; Pemetrexed

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DOCETAXEL; PEMETREXED;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; PRIORITY JOURNAL;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ANTAGONISM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; TAXOIDS; TIME FACTORS;

EID: 69049088732     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0974-0     Document Type: Article

References (23)

1. FA Shepherd 2000 Chemotherapy for advanced non-small-cell lung cancer: modest progress, many choices J Clin Oncol 18 21 Suppl 35S 38S
2. Non-Small Cell Lung Cancer Collaborative Group 1995 Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomized trials Br J Cancer 311 899 909
3. Shepherd FA, Carney DN (2000) Treatment of non-small cell lung cancer: chemotherapy. In: Hansen HH (ed) Textbook of lung cancer. Martin Dunitz, London, pp 213-242
4. M Cullen 2006 Second-line treatment options in advanced non-small cell lung cancer: current status Semin Oncol 33 1 Suppl 1 S3 S8
5. E Massarelli RS Herbst 2006 Use of novel second-line targeted therapies in non-small cell lung cancer Semin Oncol 33 1 Suppl 1 S9 S16
6. R Govindan N Page D Morgensztern, et al. 2006 Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 4539 4544
7. G Rosti O Carminati M Monti, et al. 2006 Chemotherapy advances in small cell lung cancer Ann Oncol Suppl 5 99 102
8. Socinski MA, Weissman CH, Hart LL et al (2005) A randomized phase II trial of pametrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC). Proc ASCO (a 7165)
9. Gronberg BH, Bremnes RM, Aasebo U et al, on behalf of the Norwegian Lung Cancer Study Group (2008) A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer Jun 5 [Epub ahead of print]
10. Khan RA, Hahn B (2008) Phase II trial of weekly topotecan with docetaxel in recurrent small cell lung cancer. Proc ASCO (a19111)
11. AA Adjei 2004 Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent Clin Cancer Res 10 4276S 4280S
12. N Hanna FA Shepherd FV Fossella, et al. 2004 Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 1589 1597
13. C Shih VJ Chen LS Gossett, et al. 1997 LY231514, a pyrrolo[2, 3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Res 57 1116 1123
14. JL Tonkinson P Marder SL Andis, et al. 1997 Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis Cancer Chemother Pharmacol 39 521 531
15. SE Jones J Erban B Overmoyer, et al. 2005 Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer J Clin Oncol 23 5542 5551
16. J Gligorov JP Lotz 2004 Preclinical pharmacology of the taxanes: implications of the differences Oncologist 9 Suppl 2 3 8
17. Y Kano M Akutsu S Tsunoda, et al. 2004 Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro Cancer Chemother Pharmacol 54 505 513
18. GG Steel MJ Peckham 1979 Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity Int J Radiat Oncol Biol Phys 5 85 91
19. Y Kano S Sakamoto T Kasahara, et al. 1991 In vitro effects of amsacrine in combination with other anticancer agents Leukemia Res 15 1059 1064
20. Y Kano T Ohnuma T Okano, et al. 1988 Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture Cancer Res 48 351 356
21. Y Kano K Suzuki M Akutsu, et al. 1992 Effects of CPT-11 in combination with other anticancer agents in culture Int J Cancer 50 604 610
22. Y Kano M Akutsu S Tsunoda, et al. 1994 In vitro schedule-dependent interaction between and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines Cancer Chemother Pharmacol 42 91 98
23. J Kikuchi R Shimizu T Wada, et al. 2007 E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1 Stem Cells 25 2439 2447